目的 探讨西妥昔单抗联合5-氟尿嘧啶+顺铂(5-fluorouracil+cisplatin,FP)方案对中晚期食管癌患者肿瘤标志物及外周血磷脂酰肌醇-3激酶信号通路关键蛋白(phosphatidylinositol3 kinase,PI3K)、蛋白激酶B信号通路关键蛋白(phosphorylated ...目的 探讨西妥昔单抗联合5-氟尿嘧啶+顺铂(5-fluorouracil+cisplatin,FP)方案对中晚期食管癌患者肿瘤标志物及外周血磷脂酰肌醇-3激酶信号通路关键蛋白(phosphatidylinositol3 kinase,PI3K)、蛋白激酶B信号通路关键蛋白(phosphorylated protein kinase B,pAKT)、微小核糖核酸-21(microribonucleic acid-21,miR-21)表达水平的影响。方法 将中晚期食管癌患者80例作为研究对象,用随机数字表法分为A组和B组,每组40例。A组给予FP方案治疗,B组在A组治疗的基础上加用西妥昔单抗。3周为1个周期,连续治疗4个周期。比较2组治疗后的临床疗效,治疗前、后的生存质量、功能状态、碱性成纤维细胞生长因子(basic fibroblast growth factor,bFGF)、可溶性E-钙黏蛋白(soluble E-cadherin,sE-Cad)、肿瘤标志物、PI3K、pAKT及miR-21和治疗期间的安全性。结果 治疗4个周期后,2组的总有效率比较差异无统计学意义(P>0.05)。治疗后,2组欧洲癌症研究组织生存质量测定表(European Organization for Research and Treatment of Cancer Quality of Life Questionnair,EORTC QLQ-C30)和卡氏功能状态(Karnofsky performance status,KPS)评分均升高,且B组高于A组;血清bFGF、sE-Cad、鳞状细胞癌抗原(squamous cell carcinoma antige,SCC)、癌胚抗原(carcinoembryonic antigen,CEA)、糖类抗原125(carbohydrate antigen 125,CA125)、细胞角蛋白19片段抗原(cytokeratin 19 fragment antigen21-1,CYFRA21-1)、外周血PI3K、pAKT和miR-21水平均降低,且B组低于A组(P<0.05)。2组治疗期间不良反应发生率比较差异无统计学意义(P<0.05)。结论 西妥昔单抗联合FP方案可有效降低中晚期食管癌患者肿瘤标志物水平,调节相关因子水平,改善患者血管内皮功能,进而提高患者生存质量及功能状态,临床疗效和安全性良好。展开更多
New clinical approaches are imperative beyond the widely adopted National Comprehensive Cancer Network (NCCN) guidelines, utilized by prominent cancer institutions. Cancer is the leading cause of death among individua...New clinical approaches are imperative beyond the widely adopted National Comprehensive Cancer Network (NCCN) guidelines, utilized by prominent cancer institutions. Cancer is the leading cause of death among individuals younger than 85 years within the United States. Despite significant technological advances, including the expenditure of hundreds of billions, treatment outcomes and overall survival have not notably improved for most types of advanced cancer over the last several decades. Over the past 24 years, Envita Medical Centers has pioneered a unique form of personalized treatment approach for late-stage and refractory cancer patients, introducing groundbreaking innovations in the field. Our integrated algorithm utilizes advanced genomics, transcriptomics, and highly tailored immunotherapy, resulting in remarkable outcome improvements. This study presents Envita’s innovative personalized treatment algorithms and examines the response outcomes of 199 late-stage cancer patients treated at Envita Medical Centers over a two-year period. Compared to standard of care and palliative chemotherapy, Envita’s treatment demonstrated a remarkable 35-fold improvement in overall response rates (Figure 1). Moreover, 88% of the patients, the majority presenting with Stage 3 or 4 cancer, experienced a 43-fold improvement in quality of life with minimal side effects, as compared to standard of care chemotherapy and palliative care. This revolutionary success is attributed to Envita’s personalized therapeutic algorithms, which incorporate customized immunotherapy. Envita’s precision care approach has also achieved a 100% better response rate compared to over 65 global chemotherapy clinical trials with more than 2700 patients. The results from this study suggest that a wider utilization of Envita’s personalized approach can significantly benefit patients with late-stage and refractory cancer.展开更多
文摘目的 探讨西妥昔单抗联合5-氟尿嘧啶+顺铂(5-fluorouracil+cisplatin,FP)方案对中晚期食管癌患者肿瘤标志物及外周血磷脂酰肌醇-3激酶信号通路关键蛋白(phosphatidylinositol3 kinase,PI3K)、蛋白激酶B信号通路关键蛋白(phosphorylated protein kinase B,pAKT)、微小核糖核酸-21(microribonucleic acid-21,miR-21)表达水平的影响。方法 将中晚期食管癌患者80例作为研究对象,用随机数字表法分为A组和B组,每组40例。A组给予FP方案治疗,B组在A组治疗的基础上加用西妥昔单抗。3周为1个周期,连续治疗4个周期。比较2组治疗后的临床疗效,治疗前、后的生存质量、功能状态、碱性成纤维细胞生长因子(basic fibroblast growth factor,bFGF)、可溶性E-钙黏蛋白(soluble E-cadherin,sE-Cad)、肿瘤标志物、PI3K、pAKT及miR-21和治疗期间的安全性。结果 治疗4个周期后,2组的总有效率比较差异无统计学意义(P>0.05)。治疗后,2组欧洲癌症研究组织生存质量测定表(European Organization for Research and Treatment of Cancer Quality of Life Questionnair,EORTC QLQ-C30)和卡氏功能状态(Karnofsky performance status,KPS)评分均升高,且B组高于A组;血清bFGF、sE-Cad、鳞状细胞癌抗原(squamous cell carcinoma antige,SCC)、癌胚抗原(carcinoembryonic antigen,CEA)、糖类抗原125(carbohydrate antigen 125,CA125)、细胞角蛋白19片段抗原(cytokeratin 19 fragment antigen21-1,CYFRA21-1)、外周血PI3K、pAKT和miR-21水平均降低,且B组低于A组(P<0.05)。2组治疗期间不良反应发生率比较差异无统计学意义(P<0.05)。结论 西妥昔单抗联合FP方案可有效降低中晚期食管癌患者肿瘤标志物水平,调节相关因子水平,改善患者血管内皮功能,进而提高患者生存质量及功能状态,临床疗效和安全性良好。
文摘New clinical approaches are imperative beyond the widely adopted National Comprehensive Cancer Network (NCCN) guidelines, utilized by prominent cancer institutions. Cancer is the leading cause of death among individuals younger than 85 years within the United States. Despite significant technological advances, including the expenditure of hundreds of billions, treatment outcomes and overall survival have not notably improved for most types of advanced cancer over the last several decades. Over the past 24 years, Envita Medical Centers has pioneered a unique form of personalized treatment approach for late-stage and refractory cancer patients, introducing groundbreaking innovations in the field. Our integrated algorithm utilizes advanced genomics, transcriptomics, and highly tailored immunotherapy, resulting in remarkable outcome improvements. This study presents Envita’s innovative personalized treatment algorithms and examines the response outcomes of 199 late-stage cancer patients treated at Envita Medical Centers over a two-year period. Compared to standard of care and palliative chemotherapy, Envita’s treatment demonstrated a remarkable 35-fold improvement in overall response rates (Figure 1). Moreover, 88% of the patients, the majority presenting with Stage 3 or 4 cancer, experienced a 43-fold improvement in quality of life with minimal side effects, as compared to standard of care chemotherapy and palliative care. This revolutionary success is attributed to Envita’s personalized therapeutic algorithms, which incorporate customized immunotherapy. Envita’s precision care approach has also achieved a 100% better response rate compared to over 65 global chemotherapy clinical trials with more than 2700 patients. The results from this study suggest that a wider utilization of Envita’s personalized approach can significantly benefit patients with late-stage and refractory cancer.
